KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) EPS (Basic): 2010-2025

Historic EPS (Basic) for TherapeuticsMD (TXMD) over the last 15 years, with Sep 2025 value amounting to $0.01.

  • TherapeuticsMD's EPS (Basic) rose 120.00% to $0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.01, marking a year-over-year increase of 103.57%. This contributed to the annual value of -$0.20 for FY2024, which is 79.80% up from last year.
  • According to the latest figures from Q3 2025, TherapeuticsMD's EPS (Basic) is $0.01, which was down 80.00% from $0.05 recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's EPS (Basic) ranged from a high of $17.75 in Q4 2022 and a low of -$5.70 during Q1 2022.
  • Over the past 3 years, TherapeuticsMD's median EPS (Basic) value was -$0.07 (recorded in 2023), while the average stood at -$0.11.
  • In the last 5 years, TherapeuticsMD's EPS (Basic) tumbled by 4,583.33% in 2021 and then skyrocketed by 17,850.00% in 2022.
  • Over the past 5 years, TherapeuticsMD's EPS (Basic) (Quarterly) stood at -$0.10 in 2021, then skyrocketed by 17,850.00% to $17.75 in 2022, then crashed by 100.39% to -$0.07 in 2023, then surged by 114.29% to $0.01 in 2024, then surged by 120.00% to $0.01 in 2025.
  • Its last three reported values are $0.01 in Q3 2025, $0.05 for Q2 2025, and -$0.06 during Q1 2025.